Correlation Between Esperion Therapeutics and GT Biopharma

Can any of the company-specific risk be diversified away by investing in both Esperion Therapeutics and GT Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Esperion Therapeutics and GT Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Esperion Therapeutics and GT Biopharma, you can compare the effects of market volatilities on Esperion Therapeutics and GT Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Esperion Therapeutics with a short position of GT Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Esperion Therapeutics and GT Biopharma.

Diversification Opportunities for Esperion Therapeutics and GT Biopharma

0.46

Correlation Coefficient

Esperion Therapeutics  GT Biopharma

Very weak diversification

The 3 months correlation between Esperion and GTBP is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Esperion Therapeutics and GT Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GT Biopharma and Esperion Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Esperion Therapeutics are associated (or correlated) with GT Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GT Biopharma has no effect on the direction of Esperion Therapeutics i.e., Esperion Therapeutics and GT Biopharma go up and down completely randomly.

Pair Corralation between Esperion Therapeutics and GT Biopharma

Given the investment horizon of 90 days Esperion Therapeutics is expected to under-perform the GT Biopharma. But the stock apears to be less risky and, when comparing its historical volatility, Esperion Therapeutics is 1.87 times less risky than GT Biopharma. The stock trades about -0.13 of its potential returns per unit of risk. The GT Biopharma is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  280.00  in GT Biopharma on November 29, 2024 and sell it today you would lose (44.00) from holding GT Biopharma or give up 15.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Esperion Therapeutics  vs.  GT Biopharma

Esperion Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Esperion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

GT Biopharma

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in GT Biopharma are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak fundamental drivers, GT Biopharma may actually be approaching a critical reversion point that can send shares even higher in March 2025.

Pair Trading with Esperion Therapeutics and GT Biopharma

The main advantage of trading using opposite Esperion Therapeutics and GT Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Esperion Therapeutics position performs unexpectedly, GT Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will offset losses from the drop in GT Biopharma's long position.

The idea behind Esperion Therapeutics and GT Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.